Table 2.
body weight change |
antitumor activity |
||||||
---|---|---|---|---|---|---|---|
dose (mg/kg) | animals start/end | start (g) | end (g) | % | tumor weight (g) | inhibition rate (%) | |
vehicle | 8/8 | 22.50 ± 1.23 | 26.40 ± 1.43 | 17.42 | 2.71 ± 1.07 | ||
2 | 0.25 | 8/8 | 22.44 ± 1.27 | 25.96 ± 1.54 | 15.71 | 2.23 ± 0.57 | 17.8 |
2 | 0.5 | 8/8 | 22.28 ± 1.33 | 23.85 ± 1.57 | 7.30 | 1.72 ± 0.78* | 36.8 |
2 | 1.0 | 8/8 | 22.13 ± 1.24 | 20.50 ± 3.27 | −7.23 | 1.03 ± 0.71*** | 61.9 |
paclitaxel | 15 | 8/8 | 22.50 ± 1.29 | 23.59 ± 2.66 | 4.99 | 1.08 ± 0.78** | 60.4 |
Administration by iv. Schedule: Q5D × 4, that is, every 5 days for 3 weeks. Data are presented as the mean ± SD
p < 0.05
p < 0.01
p < 0.001 vs control.